Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348208 | 0.82 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL6282434 | 0.82 | ALDH1A1 (0.54) | TSHRALDH1A1TP53 | |
| SCHEMBL959151 | 0.72 | — | — | |
| SCHEMBL5320589 | 0.69 | TSHR (0.41) | TSHRALDH1A1TP53THRB | |
| SCHEMBL4644506 | 0.69 | — | — | |
| Pivalate SCHEMBL11550946 | 0.69 | TSHR (0.71) | TSHRALDH1A1TP53THRB | |
| SCHEMBL3077314 | 0.67 | ALDH1A1 (0.35) | TSHRALDH1A1 | |
| SCHEMBL17953040 | 0.67 | ALDH1A1 (0.35) | TSHRALDH1A1 | |
| SCHEMBL6151164 | 0.67 | CA2 (0.32) | TSHRALDH1A1 | |
| SCHEMBL10544155 | 0.65 | TSHR (0.36) | TSHRALDH1A1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210584-A1 | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-28 | — | — | EP | disclosed |
| US-20090163450-A1 | COMBINATIONS COMPRISING A PROSTAGLANDIN AND USES THEREOF | BAYER SCHERING PHARMA AG (DE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009074233-A1 | SURFACE-MODIFIED NANOPARTICLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070521-A1 | Surface-modified nanoparticles | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009068190-A2 | COMBINATIONS COMPRISING A PROSTAGLANDIN AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-2065054-A1 | Combinations comprising a prostaglandin and uses thereof | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163450-A1 | COMBINATIONS COMPRISING A PROSTAGLANDIN AND USES THEREOF | TUBB3, TUBB, PTGES2 | TSHR 4549/4885ALDH1A1 2420/4885TP53 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.